Viswa Colluru, Enveda Biosciences CEO
'As the market has turned': Enveda secures $68M to move revised pipeline into the clinic in 2023
Enveda Biosciences will enter the clinic next year with at least one of its three main programs thanks to a $68 million boost in financing — about $55 million via equity and the remainder debt.
Founded by an early employee at AI startup Recursion Pharmaceuticals, Enveda has adjusted its priorities since disclosing a $51 million Series A in June 2021. At the time, CEO Viswa Colluru told Endpoints News the three core areas were Wilson disease, NASH and Parkinson’s.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
